Intensity Therapeutics, Inc. Common stock (INTS) - Total Liabilities
Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has total liabilities worth $2.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Intensity Therapeutics, Inc. Common stoc operating cash flow efficiency to assess how effectively this company generates cash.
Intensity Therapeutics, Inc. Common stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Intensity Therapeutics, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Intensity Therapeutics, Inc. Common stoc's assets to evaluate the company's liquid asset resilience ratio.
Intensity Therapeutics, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Plasma Technology U Co.Ltd
KQ:054410
|
Korea | ₩39.75 Billion |
|
Sable Resources Ltd
V:SAE
|
Canada | CA$2.82 Million |
|
Hantop Inc
KQ:002680
|
Korea | ₩91.00 Billion |
|
New Age Metals Inc
V:NAM
|
Canada | CA$249.23K |
|
Kiang Huat Sea Gull Trading Frozen Food Public Company Limited
BK:CHOTI
|
Thailand | ฿1.74 Billion |
|
Bayhorse Silver Inc
V:BHS
|
Canada | CA$2.49 Million |
|
Integra Essentia Limited
NSE:ESSENTIA
|
India | Rs859.29 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Intensity Therapeutics, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Intensity Therapeutics, Inc. Common stoc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intensity Therapeutics, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intensity Therapeutics, Inc. Common stock (2019–2024)
The table below shows the annual total liabilities of Intensity Therapeutics, Inc. Common stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.86 Million | -54.88% |
| 2023-12-31 | $4.13 Million | -75.48% |
| 2022-12-31 | $16.86 Million | +21.26% |
| 2021-12-31 | $13.90 Million | +18.72% |
| 2020-12-31 | $11.71 Million | +795.60% |
| 2019-12-31 | $1.31 Million | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical tr… Read more